http://www.fpnotebook.com/
Tamoxifen
Aka: Tamoxifen- See Also
- Indications
- Breast Cancer in post-menopausal women
- Estrogen Receptor positive
- Breast Cancer in post-menopausal women
- Contraindications
- Thromboembolism history
- Perioperative period
- Prolonged immobilization
- Efficacy
- Estrogen Receptor Positive Breast Cancer
- Reduces Breast Cancer recurrence (29%)
- Reduces mortality from Breast Cancer (20%)
- Reference
- Estrogen Receptor Positive Breast Cancer
- Course
- Recommended for five years (exact course unclear)
- Benefits
- Anti-Estrogen
- Reduces Breast Cancer recurrence rate
- Preserves Bone Mineral Density
- Only applies to post-menopausal patients
- Bone Mineral Density decreases if premenopausal
- Lowers Total Cholesterol and LDL Cholesterol
- Only applies to post-menopausal patients
- No effect on lipids if premenopausal
- Anti-Estrogen
- Adverse Effects
- Thromboembolism
- Tamoxifen significantly increases risk
- See contraindications
- Endometrial Cancer
- Markedly increased risk if used more than 5 years
- Relative risk for 2 to 5 years of use: 2.0
- Relative risk for 5 or more years of use: 6.9
- Thromboembolism
- Drug Interactions
- CYP2D6 Inhibitors (e.g. Paroxetine, Fluoxetine)
- May decrease Tamoxifen efficacy
- CYP2D6 Inhibitors (e.g. Paroxetine, Fluoxetine)
- References